Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Innate Pharma
Innate Pharma specializes in the research and development of immunological-based drugs for cancers and infectious diseases treatment. The drug candidates belong to a new therapeutic class and are monoclonal antibodies targeting mechanisms of regulation of a particular compartment in our immune system: the innate immunity. This approach receives validating partnerships with 2 main players of the biopharmacy: Bristol-Myers Squibb in the cancer field and Novo Nordisk in the inflammation signs. Net sales break down by source of income as follows:

- income from partnership and licensing agreements (85%);

- federal subsidies (15%).

At the end of 2018, the company held a portfolio of 3 products in clinical development including 2 in phase II (IPH4102 for the treatment of cutaneous T-cell lymphomas and Monalizumab for the treatment of cancer) and 1 in phase I (IPH5401 for the treatment of solid tumors), and 4 in preclinical development phase (treatment of cancer and inflammatory diseases).
Sales per Businesses
20172018Delta
EUR (in Million)%EUR (in Million)%
Therapeutic Antibodies32.63100%79.89100% +144.83%
Sales per Regions
20172018Delta
EUR (in Million)%EUR (in Million)%
France32.63100%79.89100% +144.83%
Managers
NameAgeSinceTitle
Mondher Mahjoubi, Dr.612016Chairman-Executive Board & Chief Executive Officer
Hervé Brailly, Dr.58-Chairman-Supervisory Board
Laure-Hélène Mercier422019CFO & Member-Executive Board
Eric Vivier, Dr.552018Chief Scientific Officer & Senior Vice President
Pierre F. Dodion, Dr.652014Chief Medical Officer & Executive VP
Odile Belzunce382019Senior VP-Compliance & Information Technology
Patrick J. Langlois, Dr.742010Member-Supervisory Board
Irina Staatz-Granzer, Dr.592012Vice Chairman-Supervisory Board
Gilles Brisson672016Member-Supervisory Board
Véronique Chabernaud, Dr.582015Member-Supervisory Board
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 78,560,464 59,777,703 76.1% 18,575 0.0% 76.1%
Shareholders
NameEquities%
Novo Nordisk A/S 9,817,546 12.4%
AstraZeneca PLC 6,260,500 7.93%
Bpifrance Participations SA /PRIVATE EQUITY/ 4,396,682 5.57%
Invesco Advisers, Inc. 1,000,000 1.27%
Hervé Brailly 979,784 1.24%
BlackRock Fund Advisors 674,423 0.85%
Wellington Management Co. LLP 650,252 0.82%
Exane Asset Management SA 475,000 0.60%
Schroder Investment Management Ltd. 341,522 0.43%
HSBC Global Asset Management (France) SA 327,335 0.41%
Holdings
NameEquities%Valuation
Innate Pharma (IPH) 18,5750.024%129,666 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Euronext Paris
- Compartiment B
- CAC All Shares / CAC All-Tradable, CAC Mid Small, CAC PME, CAC Small, EnterNext© PEA-PME 150, Next 150, Next Biotech, PEA, PEA-PME, Tech 40
Stock Exchange Codes
- Bloomberg Code :  IPH:FP
- Reuters Code :  IPH.PA
- Datastream Code :  
Company contact information
Innate Pharma
117 Avenue de Luminy
BP 30191
FR-13009 Marseille
France

Phone : +33 (0)4 30 30 30 30
Fax : +33 (0)4 30 30 30 00
Internet : http://www.innate-pharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Innate Pharma
Sector Biotechnology & Medical Research - NEC